EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ORUM (475830) fair value: what the stock is really worth

As of Sep 29, 2026: fair value of ORUM KRW 4,518, price KRW 22,500, upside -79.9%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7475830006

O Thin data Sep 24, 2026

ORUM

475830 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 4,518 KRW · Strongly overvalued (−79.9%)
!Quality 24/100
!Weak Growth (revenue 3y −32.3 %/yr)
!Low debt · negative free cash flow
!Trails peers (1/7)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch ORUM for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

143,700 KRW 17,010 KRW Fair Value 4,518 KRW Feb 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

19‑month range 17,010 KRW – 143,700 KRW · fair‑value band 2,982 KRW – 5,648 KRW · the 22,500 KRW price screens above the 4,518 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow ORUM in your weekly email

Every Wednesday you see whether ORUM is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States.

Show more

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs. The company was founded in 2016 and is headquartered in Daejeon, South Korea.

Stock analysis

ORUM (475830) currently trades at 22,500 KRW, while our model-based Fair Value estimate is 4,518 KRW, 79.9% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: 2,982 KRW (bear) to 5,648 KRW (bull), the price of 22,500 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ORUM reported revenue of 23.6M KRW in FY2025 versus 75.9M KRW in FY2022, a compound −32.3%/yr. Reported net income was −42.0B KRW in FY2025.

Key figures

Market cap 1.4T KRW (≈ $1.0B) · Return on equity −22.4% · Return on assets (EBIT) −45.5% · Operating margin −292,398% · Revenue (TTM) 20.6M KRW · Revenue growth (YoY) −77.5% · Free cash flow −36.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 84% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, 475830 screens richer than that median.

Fair Value models

Bear 2,982 KRW Fair Value 4,518 KRW Bull 5,648 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 3,082 KRW 4,130 KRW 6,165 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 3,082 KRW 4,130 KRW 6,165 KRW 54

Open the full fair value analysis →

Notify me when 475830 reaches fair value

Put 475830 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 24/100

Of which business quality 29 · Market factors (momentum, volatility) 11

Profitability 0
Margins and returns on capital today
Quality Growth 13
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 74
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−99.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−57,492.6% (2022) → −219,651.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

475830 screens overvalued: fair value 80% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ORUM with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −79.9% · Bottom 25%
Profitability
Return on assets −14.9% · Below median
Growth and dividend
Revenue growth −77.5% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 50.38× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ORUM · Fair Value
4,518 KRW −80%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ORUM Fair Value". https://www.fairvalue-calculator.com/stock/475830

Frequently asked questions

Is ORUM (475830) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,518 KRW versus a price of 22,500 KRW, about −80% upside (overvalued).
What is the fair value of 475830?
Our model-based fair value for ORUM is 4,518 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 22,500 KRW.
What is the quality score of 475830?
ORUM has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ORUM (475830)?
Our model-based price target is the fair value of 4,518 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2,982 KRW, optimistic scenario 5,648 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ORUM stock forecast for 2026?
Our models put fair value at 4,518 KRW, about −80% upside versus a price of 22,500 KRW (overvalued). Cautious scenario 2,982 KRW, optimistic scenario 5,648 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ORUM (475830)?
ORUM reported trailing-twelve-month revenue of about 20.6M KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ORUM (475830)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ORUM it is 4,518 KRW per share (as of Sep 24, 2026), against a price of 22,500 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ORUM stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 475830 trades above its calculated fair value: price 22,500 KRW, fair value 4,518 KRW, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 475830?
No. The price is what the market pays today (22,500 KRW); the fair value is what the company's own numbers justify (4,518 KRW). For ORUM the two are 17,982 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ORUM worth?
The market values ORUM at about 1.4T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 22,500 KRW; our models calculate a fair value of 4,518 KRW per share.
What do the bullish and bearish scenarios say about 475830?
Our models span a range for ORUM: cautious scenario 2,982 KRW, base 4,518 KRW, optimistic 5,648 KRW per share (as of Sep 24, 2026, price 22,500 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ORUM (475830)?
Balance-sheet figures for ORUM (as of Sep 24, 2026): return on equity −22.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 475830 from its 52-week high?
ORUM trades at 22,500 KRW, about 84% below its 52-week high of 143,700 KRW and at the low of 22,500 KRW (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of 4,518 KRW is for.
Which stocks are comparable to ORUM?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ORUM stock attractive at the current price?
The data as of Sep 24, 2026: price 22,500 KRW, calculated fair value 4,518 KRW (−80%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 475830 calculated?
We run ORUM through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,518 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. ORUM itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ORUM (475830)?
The closing price on Sep 29, 2026 was 22,500 KRW. Our model-based fair value is 4,518 KRW, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ORUM right now?
The price sits above even our optimistic bull case (5,648 KRW). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,982 KRW to 5,648 KRW) leaves room in how you read the outcome.

Key figures of ORUM

How large is the market capitalisation of ORUM (475830)?
The market capitalisation of ORUM is 1.4T KRW (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of ORUM (475830)?
The return on equity (ROE) of ORUM is −22.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ORUM (475830)?
On an EBIT basis the return on assets of ORUM is −45.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ORUM (475830)?
The operating margin of ORUM is −292,398% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ORUM (475830)?
Revenue at ORUM is growing −77.5% versus a year earlier (3y avg −32.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ORUM (475830) generate?
The free cash flow of ORUM is −36.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch ORUM in the live analysis

One click puts ORUM on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.